MARKET

DSGN

DSGN

Design Therapeutics, Inc.
NASDAQ
13.30
-0.14
-1.04%
Opening 13:02 06/26 EDT
OPEN
13.44
PREV CLOSE
13.44
HIGH
13.67
LOW
13.13
VOLUME
258.45K
TURNOVER
--
52 WEEK HIGH
17.25
52 WEEK LOW
3.330
MARKET CAP
830.68M
P/E (TTM)
-11.1437
1D
5D
1M
3M
1Y
5Y
1D
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Seeking Alpha · 1d ago
10 small-cap U.S. healthcare stocks with the strongest momentum grades
Seeking Alpha · 2d ago
Weekly Report: what happened at DSGN last week (0615-0619)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), SAB Biotherapeutics (SABS) and Design Therapeutics (DSGN)
TipRanks · 06/15 11:50
Weekly Report: what happened at DSGN last week (0608-0612)?
Weekly Report · 06/15 10:03
Design Therapeutics Stockholders Approve Director and Auditor at Meeting
TipRanks · 06/11 21:13
Design Therapeutics shareholders elect Simeon George to board at annual meeting
PUBT · 06/11 20:05
Weekly Report: what happened at DSGN last week (0601-0605)?
Weekly Report · 06/08 10:00
More
About DSGN
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Webull offers Design Therapeutics Inc stock information, including NASDAQ: DSGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DSGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DSGN stock methods without spending real money on the virtual paper trading platform.